The Folate and Cancer Question: Why Megadosing With Methylfolate Isn't Risk-Free

The relationship between folate and cancer is one of the most nuanced and frequently misunderstood areas in nutritional research. You may have come across claims that methylfolate prevents cancer, or alternatively, that high-dose folate supplementation promotes cancer. Both positions contain elements of truth — and the reality is considerably more complex than either simple narrative.

Folate and DNA Integrity

Folate is essential for DNA synthesis and repair. Adequate folate maintains the nucleotide pool needed for DNA replication and supports the methylation of DNA itself — a process that regulates gene expression and suppresses proto-oncogene activation. Folate deficiency is associated with DNA damage, uracil misincorporation into DNA, and impaired repair — all of which increase cancer risk.

The Dual Role Problem

Here is where it gets complicated. The same folate-dependent processes that support normal cell division also support the division of cancer cells once a tumour is established. Folate is essential for cell growth — and cancer cells, which grow rapidly, require folate in large quantities. This is the basis for methotrexate — a folate antagonist used as a chemotherapy drug, which kills rapidly dividing cells by blocking folate metabolism.

The implication: adequate folate status appears protective against cancer initiation (by maintaining DNA integrity and suppressing oncogene expression), but high-dose folate supplementation in people with existing pre-cancerous lesions or established tumours may potentially accelerate progression. This dual timing-dependent effect — sometimes called the folate paradox — is supported by epidemiological evidence.

Folic Acid Specifically: The Unmetabolised Problem

The risk associated with high folate intake is more specifically associated with folic acid — the synthetic form — rather than natural food folate or methylfolate. Unmetabolised folic acid (UMFA) accumulates in the bloodstream in people who consume more folic acid than their MTHFR enzyme can convert. UMFA has been associated in some research with impaired natural killer cell function — potentially reducing immune surveillance of pre-cancerous cells. This concern is specific to folic acid and does not apply to methylfolate, which is used directly without requiring MTHFR conversion.

The Practical Position

For people with MTHFR variants, switching from folic acid to methylfolate at standard nutritional doses (400-800mcg) is prudent. This avoids UMFA accumulation while maintaining the DNA integrity and methylation support that adequate folate provides. Megadosing methylfolate beyond established needs without clinical indication is not supported by evidence and introduces unnecessary uncertainty.

NeuroThrive™ products are food supplements and are not intended to diagnose, treat, or cure any medical condition. If you have a cancer diagnosis or history, please discuss supplementation with your oncologist before making changes.